Skip to main content
. 2018 Mar 6;39(5):2055–2062. doi: 10.3892/or.2018.6299

Table III.

MBI results in residual breast cancer detection after neoadjuvant therapy in the 43 patients enrolled in the study, 7 without and 36 with residual disease after neoadjuvant therapy.

Parameters Data
Negative   7
False-positive   0
Positive 34
False-negative   2
Sensitivity 94.4% (34/36)
Specificity 100% (7/7)
Accuracy 95.3% (41/43)
Positive predictive value 100% (34/34)
Negative predictive value 77.8% (7/9)

MBI, molecular breast imaging.